Taysha Gene Therapies, a biotech company developing gene therapies for severe CNS diseases, will release its Q2 2026 financial results on August 11, 2026. The company will also hold a conference call and webcast to provide updates on its progress, including its lead program TSHA-102 for Rett syndrome. This event offers investors insight into the company’s development pipeline and strategic direction. An archived replay will be available on Taysha’s website after the live event.
Tokenized equity trading volume reached nearly $3 billion weekly in August, driven mainly by Robinhood Chain, BNB Chain, and Solana. Despite this growth, only about 5% of tokenized stocks are used in onchain financial applications, with total value l...
Ethereum is set to upgrade its network with EIP-8141, introducing 'frame transactions' that split one transaction into up to 64 programmable frames. This new transaction type enables native account abstraction, gas sponsorship, and atomic batching, a...
As of June 30, 2026, thirty institutional investors collectively held about $74.9 million in Hyperliquid ETF products, with Brazil's Wealth High Governance Asset Management leading at nearly $24 million in the 21Shares' THYP fund. These ETFs track th...
Useless Coin (USELESS) hit a 10-month high of $0.286 after rallying 300% in a week, driven by strong buying and new holders. Despite intense buying pressure and positive momentum indicators, the rally may be overextended, suggesting a potential pullb...
The Seattle Times and Newsday have filed lawsuits against OpenAI and Microsoft, accusing them of using their journalism content without permission to train AI models. The lawsuits warn that generative AI could severely damage the journalism industry ...
